A prolonged FCC review against a backdrop of President Donald Trump’s lawsuit is fueling speculation that a Paramount–Skydance marriage may be heading for the rocks.    In a note Wednesday, analyst Rich Greenfield of LightShed Partners voiced what others have started to wonder, saying he’s “increasingly concerned the deal could collapse as Paramount is paralyzed by legal fears surrounding the pending President Trump–CBS 60 Minutes lawsuit.” The proposed merger announced last summer carried several automat ...

Group 1: Apple App Store Performance - Apple's App Store revenue for May increased by 4.9% month-over-month, surpassing the historical average of 2.3% for this period, leading to a year-over-year revenue growth of 13.0% in May compared to 11.8% in April [1] - App Store downloads rose by 2.0% month-over-month in May, contrasting with a decline of 4.6% in April, and showed a year-over-year increase of 3.1% in May, down from 5.8% in April [3] Group 2: Analyst Insights and Forecasts - Analyst Samik Chatterjee maintains an Overweight rating on Apple, indicating confidence in the company's performance despite the lack of official guidance for Services revenue growth [1][2] - Monthly revenue trends for the App Store are expected to support low-double-digit year-over-year growth in Services, aligning with Chatterjee's forecasts [2] Group 3: Smartphone Market Concerns - Counterpoint Research has revised global smartphone shipment growth expectations for 2025 down to 1.9% from 4.2%, attributing this to tariff-related uncertainties [4] - IDC forecasts U.S. smartphone shipment growth to be 1.9% in 2025, a decrease from 3.3% in 2017, also due to tariff-related price increases [5] - Deepwater Research's Gene Munster suggests Apple has about two years to refine its AI strategy, which will necessitate increased investments [5]

Core Insights - The article discusses Intel Corporation's stock performance and management credibility issues under former CEO Pat Gelsinger, suggesting a buying opportunity as the stock price had dropped significantly from around $30 [1]. Group 1: Company Performance - Intel's stock price experienced a decline, prompting the suggestion to buy shares due to the perceived undervaluation [1]. Group 2: Management Credibility - There were concerns regarding management credibility during the tenure of former CEO Pat Gelsinger, which may have impacted investor confidence [1].

Shares of Advanced Micro Devices (AMD 1.14%) were moving higher last month after the chipmaker posted better-than-expected results in its first-quarter earnings report, signed a deal with a Saudi Arabian artificial intelligence (AI) start-up, and benefited from the broader recovery trend in the market as investors seemed to look past tariff concerns.As a result, AMD finished the month up 14%, according to data from S&P Global Market Intelligence. As you can see from the chart, most of the stock's gains came ...

Core Viewpoint - Crown Castle Inc. is positioned as a digital infrastructure company, focusing on enhancing its asset portfolio and strategic direction in response to recent developments in the industry [8]. Group 1: Company Overview - Crown Castle has experienced significant changes over the past nine months, indicating a dynamic approach to its operations and market positioning [9]. Group 2: Leadership and Participation - The conference call features key company participants, including Interim CEO Daniel K. Schlanger and CFO Sunit Patel, highlighting the leadership's engagement with investors and analysts [2][3].

Core Points - Oil-Dri Corporation of America has declared a $0.18 quarterly cash dividend per share of Common Stock and $0.135 per share of Class B Stock, marking a 16% increase for both classes and the 22nd consecutive year of dividend growth [1][2][3] - The company has paid cash dividends continuously since 1974, showcasing its sustained fiscal strength and disciplined capital management [2] - The dividend increase reflects the company's strong financial position and confidence in its future, emphasizing a commitment to delivering long-term value to stockholders [3] Company Overview - Oil-Dri Corporation is a leading manufacturer and supplier of specialty sorbent products across various markets, including pet care, animal health, fluids purification, and agriculture [5] - The company is vertically integrated, allowing it to efficiently manage all aspects of its operations from research and development to marketing and sales [5] - With over 80 years of experience, Oil-Dri aims to create value from sorbent minerals [5] Upcoming Events - The company will release its performance report for the third quarter of fiscal year 2025 after the U.S. stock market closes on June 5, 2025 [4] - An earnings discussion will be hosted via a live webcast on June 6, 2025, at 10:00 a.m. Central Time [4]

Core Insights - Lifeway Foods, Inc. has achieved net sales of $37.6 million for the first two months of Q2 2025, marking a 10.7% increase year-over-year [1] - Year-to-date net sales reached $83.7 million as of May 31, 2025, with expectations for Q2 net sales to be between $52 million and $56 million [1] - The company is expanding distribution of its products in response to rising consumer interest in probiotic and functional foods [2] Sales Performance - The company reported a 10.7% increase in net sales for the first two months of Q2 2025 compared to the same period last year [1] - Year-to-date net sales as of May 31, 2025, totaled $83.7 million [1] - Lifeway anticipates Q2 net sales to fall between $52 million and $56 million [1] Product Expansion - Lifeway is expanding its distribution across major retailers, including Amazon Fresh, BJ's Wholesale Club, CVS, HEB, and others [3] - New product launches include Lifeway Organic, Lactose Free Flavor Fusions and Lifeway Organic Kefir Shots in various retail locations [3] - The company is seeing a 63% unit increase in Lifeway Farmer Cheese year-to-date, indicating strong demand [2] Market Trends - There is a growing consumer interest in functional foods that support gut health and overall wellness, driven by social media trends [2] - Lifeway's products are made with live and active cultures, aimed at supporting immunity, digestion, and long-term health [2]

Core Viewpoint - Fly-E Group, Inc. has successfully closed a public offering of 28,595,553 shares of common stock and 57,191,106 warrants, raising approximately $6.94 million in gross proceeds, which will be used for inventory purchases, production costs, and working capital [1][2]. Group 1: Offering Details - The public offering price was set at $0.2428 per share, with each share sold together with two warrants, each exercisable at an exercise price of $0.2913 [1][2]. - The offering closed on June 4, 2025, and the warrants are exercisable immediately, expiring on the fifth anniversary of the issuance date [1][2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards purchasing inventory, covering production costs of vehicles, and supporting working capital needs [2]. Group 3: Company Overview - Fly-E Group, Inc. specializes in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters under the brand "Fly E-Bike," promoting eco-friendly transportation [5].

Core Insights - Bio-Path Holdings, Inc. is a clinical-stage biotechnology company focused on RNA interference therapeutics using its DNAbilize® platform [1] - The lead candidate, prexigebersen (BP1001), is in Phase 2 trials for acute myeloid leukemia (AML) and shows potential for FDA approval [7] - Bio-Path is advancing its pipeline with multiple candidates targeting various cancers and metabolic diseases [1][7] Company Overview - Bio-Path Holdings, Inc. is based in Bellaire, Texas and specializes in RNAi therapeutics [1] - The company employs a proprietary liposomal delivery system to enhance drug stability and cellular uptake while reducing toxicity [1] Pipeline Development - Prexigebersen (BP1001) targets the Grb2 protein and is currently in Phase 2 trials for AML [1] - A modified version, BP1001-A, is in Phase 1/1b trials for solid tumors and has shown early efficacy [7] - Another candidate, BP1002, targets the Bcl-2 protein for blood cancers and solid tumors [1] - Bio-Path is preparing an IND application for BP1003, a STAT3 inhibitor for pancreatic cancer [1]

Group 1 - The total number of shares of the company as of May 30, 2025, is 136,973,697 [1] - The total gross of voting rights is 136,973,697 [1] - The total net of voting rights, after excluding shares without voting rights, is 136,738,528 [1]